Cogent Biosciences Inc (NASDAQ:COGT) has a beta value of 1.67 and has seen 0.5 million shares traded in the recent trading session. The company, currently valued at $665.37M, closed the recent trade at $5.84 per share which meant it lost -$0.15 on the day or -2.43% during that session. The COGT stock price is -115.92% off its 52-week high price of $12.61 and -0.68% below the 52-week low of $5.88. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.28 million shares traded. The 3-month trading volume is 1.37 million shares.
The consensus among analysts is that Cogent Biosciences Inc (COGT) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.58.
Cogent Biosciences Inc (NASDAQ:COGT) trade information
Sporting -2.43% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the COGT stock price touched $5.84 or saw a rise of 15.73%. Year-to-date, Cogent Biosciences Inc shares have moved -25.07%, while the 5-day performance has seen it change -15.30%. Over the past 30 days, the shares of Cogent Biosciences Inc (NASDAQ:COGT) have changed -16.51%. Short interest in the company has seen 11.84 million shares shorted with days to cover at 9.77.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 58.29% from the levels at last check today. The projected low price target is $14.0 while the price target rests at a high of $14.0. In that case, then, we find that the latest price level in today’s session is -139.73% off the targeted high while a plunge would see the stock gain -139.73% from the levels at last check today.
Cogent Biosciences Inc (COGT) estimates and forecasts
The company’s shares have lost -46.38% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.02% over the past 5 years. Earnings growth for 2025 is a modest 9.38% while over the next 5 years, the company’s earnings are expected to increase by 31.60%.
COGT Dividends
Cogent Biosciences Inc is expected to release its next earnings report on 2025-Feb-24 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cogent Biosciences Inc (NASDAQ:COGT)’s Major holders
Insiders own 0.16% of the company shares, while shares held by institutions stand at 108.06% with a share float percentage of 108.23%. Investors are also buoyed by the number of investors in a company, with Cogent Biosciences Inc having a total of 232.0 institutions that hold shares in the company. The top two institutional holders are POINT72 ASSET MANAGEMENT, L.P. with over 10.47 million shares worth more than $88.27 million. As of 2024-06-30, POINT72 ASSET MANAGEMENT, L.P. held 10.5506% of shares outstanding.
The other major institutional holder is COMMODORE CAPITAL LP, with the holding of over 9.74 million shares as of 2024-06-30. The firm’s total holdings are worth over $82.09 million and represent 9.8126% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund. As of Dec 31, 2024, the former fund manager holds about 2.89% shares in the company for having 3.29 shares of worth $19.3 million while later fund manager owns 2.58 shares of worth $15.13 million as of Dec 31, 2024, which makes it owner of about 2.27% of company’s outstanding stock.
